GlaxoSmithKline (GSK), the second largest drug maker in the world, has announced that the company will set up a new manufacturing production line in Nashik, Maharashtra to manufacture 300 million tablets of albendazole per year for the treatment of Lymphatic Filariasis (LF).

Also Read

News Now
Paper
Specials

- Nervous markets wait for global cues
- No global M&A plans, better opportunities in India: ICICI
- India Inc’s global buyout to go beyond $14 bn
- ArcelorMittal bullish on profits despite global crunch
- SBI ranks low in employee productivity: RBI
- Inject Rs 1,00,000 cr; cut CRR & repo rate: Industry bodies
More

Also Read

News Now
Paper
Specials

- TCS acquires Citigroup Global Services for $505 million
- Domestic funds help market recover from early crash
- Govt may ease ECB norms further
- Benchmark rates cut in concerted move
- Venture investors hold & ‘Come to Jesus’ meet
More

Also Read

News Now
Paper
Specials

- Subprime Crisis: US faces economic turmoil
- Fighting Inflation : Inflation at a 13-year high
- Your Money : Personal finance
- Credit Policy : RBI’s monetary policy review
- Tracking the downturn : Economic slowdown and its impact
- Time Out : food, travel, sports, health…

More

Production will begin in late 2008 and will double GSK’s current global albendazole capacity. GSK will invest nearly Rs 17 lakh in the facility as well as converting existing equipment to produce the tablets for donation, said a GSK press release.

Worldwide more than 1.3 billion people live at risk of disability and disfigurement caused by LF, and one-third of those at risk live in India. WHO’s Global Programme to Eliminate Lymphatic Filariasis, uses once-yearly treatment of at-risk individuals using albendazole plus either Mectizan or diethylcarbamazine [DEC), supplied by GSK and Merck & Co. Since the programme began in 2000, more than 1.9 billion treatments have been given to over 570 million people in 48 of the 83 countries with endemic LF, said the release.

Related Content

Subscribe to the post comments feeds or Leave a trackback